Accelerate Diagnostics — 38th Annual J.P. Morgan Healthcare Conference 2020
23 slides from Accelerate Diagnostics's conference presentation, Jan 15, 2020

Slide 1: 38th Annual J.P. Morgan Healthcare Conference
38TH ANNUAL J.P. Morgan Healthcare Conference Jack Phillips Incoming CEO January 2020

Slide 2: Cautionary Note On Forward-Looking Statements
Cautionary Note On Forward-Looking Statements © Copyright 2020 Accelerate Diagnostics, Inc. All Rights Reserved. The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc. All other trade

Slide 3: Our Purpose and Mission
OUR PURPOSE We deliver lifesaving answers for patients with serious infections 3 OUR MISSION Expand our market leadership in Rapid ID/AST by delivering innovation with clear clinical and financial value for health systems and patients

Slide 4: Sepsis: 270,000 deaths in U.S. annually
270,000 deaths in U.S. annually1 AIDS Breast Cancer Prostate Cancer Lung Cancer SEPSIS 1 in 3 patient deaths in U.S. hospitals 1. Centers for Disease Control and Prevention (cdc.gov/sepsis/datareports) 2. Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP): http

Slide 5: Optimizing antibiotics within the first hours is critical
Optimizing antibiotics within the first 24 hours is critical 80% of sepsis deaths could be prevented with rapid diagnosis and treatment 7.6% decrease in chance of survival per hour of delay of effective therapy Kumar A, et al. Duration of hypotension before initiation of effective antimicrobial ther

Slide 6: Today's standard of care
Today’s standard of care Can take up to 69 hours ‘TIME TO RESULT ‘TIME TO OPTIMAL THERAPY TTR TTOT CONVENTIONAL METHODS. 40 48 56 64 n HouRS ACCELERATE

Slide 7: The New Standard of Care: Accelerate Pheno system
The New Standard of Care Accelerate Pheno® system 7 1. Texas Health Huguley Hospital. Self-reported data (October 2019). 2. University of Iowa Health Care. Data presented at IDWeek™ (October 2019).

Slide 8: Patient & Economic Impact of rapid action based on Accelerate Pheno results
Patient & Economic Impact of rapid action based on Accelerate Pheno® results T–12 hrs Blood drawn, patient started on empiric therapy (cefepime) 8 hrs TTR: Accelerate Pheno® system results: multi-drug-resistant E. coli 12 hrs TTOT: Patient therapy changed to meropenem 9 CHILDREN’S HOSPITAL LOS ANGEL

Slide 9: The ID/AST Testing Market
The ID/AST Testing Market First mover advantage on substantial IVD market 10 ID/AST restated market value1 $3.7B ID/AST tests per annum2 All Other Micro Samples2 Blood Resp. 135M tests North America EMEA China Total Blood: 2.3 1.9 2.5 6.7 Respiratory: 0.9 0.9 0.7 2.5 All Other Micro Samples:2 34.7 2

Slide 10: The ID/AST Testing Market
The ID/AST Testing Market First mover advantage on substantial IVD market 10 ID/AST restated market value1 $3.7B ID/AST tests per annum2 All Other Micro Samples2 Blood Resp. 135M tests North America EMEA China Total Blood: 2.3 1.9 2.5 6.7 Respiratory: 0.9 0.9 0.7 2.5 All Other Micro Samples:2 34.7 2

Slide 11: How we're doing in the market: Preliminary 2019 key results
How we’re doing in the market Preliminary 2019 key results 0 140 280 420 560 700 2017 2018 2019 $0 $2 $4 $6 $8 $10 2017 2018 2019 Gross Margin: ~50% Net Cash Burn: $58M Cash Balance: $109M Global Contracted Phenos Consolidated Revenue Other Key Results2 304 placements in 2019 $9.3M in 2019 11 78 280

Slide 12: 2020 Expectations
2020 Expectations Momentum continuing to build Revenue Net cash burn 2020 $16–18M $49M YOY% ~100% ~(15%)

Slide 13: 2020 Priorities
U.S. Commercial Excellence Focused Geographic Expansion Targeted Investments in Innovation 1 2 3 13 2020 Priorities

Slide 14: U.S. Commercial Excellence
1 U.S. Commercial Excellence 14 2020 Priorities

Slide 15: Powered by Evidence
Powered by Evidence 15 Cost Savings $3,100 /patient1 Length of Stay –6.1 days1 –4.7 days2 –2.4 days3 –5.9 days1,* –2.2 days4,* 1. Werner Forssmann Hospital. Data presented at DIVI Congress (December 2019). 2. Arnot Ogden Medical Center. Self-reported data (October 2019). 3. University of Arkansas fo

Slide 16: Customer KOLs span key geographies/segments
Customer KOLs span key geographies/segments • Current customer base enables regional referral strategy • Customers across all segments • Leverage KOL base as advocates

Slide 17: Reengineering go-live process
Reengineering go-live process Improving time from contract to reliable annuity § Overhauled process in 4Q19 § Operational focus to improve multi-site delays § Long-term goal is 50% reduction to go-live $45k $102k Live Pheno Instruments + Not Yet Live US Annuity Current Average Per Instrument Annuity

Slide 18: Focused Geographic Expansion
2 Focused Geographic Expansion 18 2020 Priorities

Slide 19: Update on Non-US Markets
Update on Non-US Markets EMEA China § An important long-term market § Focus on improving annuity § Leveraging mounting clinical evidence to expand utility from current ICU niche to all blood testing § Initiated NMPA registration/trial process § Building KOL network affiliated with China National Act

Slide 20: Targeted Investments in Innovation
Targeted Investments 3 in Innovation 20 2020 Priorities

Slide 21: Targeted Investments in Innovation
Targeted Investments in Innovation Accelerate Pheno® System Assay Expansion § Current blood test improvements: new drugs and AST features § Respiratory: analytical studies ongoing Next Generation Platform § Low-cost / high-throughput § Unlocks other clinical micro samples § Established multiplex cap

Slide 22: Growth Strategy
Growth Strategy Platform innovation & geographic plan significantly expands available market1 $1.0B Current Addressable Market $3.7B 22 Adding Lower Respiratory Assay Expansion into China Blood Market Expanding Lab Footprint with Low Acuity Samples $1.3B $2.0B § Mature gross margins of ~70% § Strate

Slide 23: Summary
Summary WHO WE ARE A diagnostics company based in Arizona, founded in 2012, with a mission of reducing the impact of sepsis and antibiotic resistance through rapid diagnosis of serious infections. THE PROBLEM Due to the overuse of antibiotics, the human and hospital costs of treating conditions like
Source: SEC EDGAR · 8-K filed Jan 15, 2020


